Inventor · disambiguated record
Shelia M. Violette
Also filed as: VIOLETTE SHELIA · VIOLETTE SHELIA M · VIOLETTE SHELIA MARIE
12 granted patents·13 pending applications·146 citations·filing 2003–2023
90Inventor score
Top patents by PatentIndex Score
25 records- 0194US7943742B2Anti-αvβ6 antibodies and uses thereofBIOGEN IDEC INC·Filed 2006·Granted May 17, 2011·29 cites·14 claims
- 0294US7465449B2Anti-αvβ6 antibodiesBIOGEN IDEC INC·Filed 2003·Granted Dec 16, 2008·71 cites·58 claims
- 0392US11053305B2Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptideQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·6 cites·35 claims
- 0491US8153126B2Anti-αvβ6 antibodiesVIOLETTE SHELIA M·Filed 2008·Granted Apr 10, 2012·25 cites·16 claims
- 0588US11053306B2Fusion protein constructs comprising anti-C3d antibody and factor HQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·2 cites·28 claims
- 0684USRE44681ECompositions and methods for inhibiting growth of SMAD4-deficient cancersBIOGEN IDEC INC·Filed 2013·Granted Dec 31, 2013·3 cites·41 claims
- 0784US7927590B2Compositions and methods for inhibiting growth of smad4-deficient cancersBIOGEN IDEC INC·Filed 2007·Granted Apr 19, 2011·8 cites·29 claims
- 0873US9745376B2Anti-ανβ6 antibodiesBIOGEN MA INC·Filed 2014·Granted Aug 29, 2017·1 cites·8 claims
- 0970US2020248257A1Biomarkers for use in integrin therapy applicationsBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 1069US2022049301A1Biomarkers for use in integrin therapy applicationsBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 1168US11879008B2Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulatorQ32 BIO INC·Filed 2021·Granted Jan 23, 2024·0 cites·32 claims
- 1268US8992924B2Anti-ανβ6 antibodies and uses thereofVIOLETTE SHELIA M·Filed 2011·Granted Mar 31, 2015·1 cites·43 claims
- 1365US2015086570A1Biomarkers for use in integrin therapy applicationsBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 1462US2024301043A1METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORQ32 BIO INC·Filed 2023·Application pending·0 cites
- 1557US2009028853A1TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6UNIV CALIFORNIA A CALIFORNIA C·Filed 2007·Application pending·0 cites
- 1656US2014294809A1Anti-Alpha(v)Beta(6) Antibodies and Uses ThereofBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 1753US2012251532A1Anti-alpha v beta 6 antibodiesVIOLETTE SHELIA M·Filed 2012·Application pending·0 cites
- 1850US10035860B2Anti-alpha V beta 6 antibodies and uses thereofBIOGEN MA INC·Filed 2014·Granted Jul 31, 2018·0 cites·21 claims
- 1947US2011293512A1Compositions and Methods for Inhibiting Growth of SMAD-4 Deficient CancersVIOLETTE SHELIA M·Filed 2011·Application pending·0 cites
- 2046US10035859B2Anti-alpha V beta 6 antibodies and uses thereofBIOGEN MA INC·Filed 2014·Granted Jul 31, 2018·0 cites·21 claims
- 2143US2011287007A1Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6SHEPPARD DEAN·Filed 2011·Application pending·0 cites
- 2243US2012027754A1Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6SHEPPARD DEAN·Filed 2011·Application pending·0 cites
- 2340US2007009518A1Methods for treating fibrotic conditionsBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 2437US2016017041A1Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodiesBIOGEN MA INC·Filed 2014·Application pending·0 cites
- 2531US2017362324A1Humanized anti-alpha v beta 5 antibodies and uses thereofBIOGEN MA INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →